Delayed emesis: moderately emetogenic chemotherapy.

Abstract

Data on the incidence and efficacy of antiemetic prophylaxis against delayed emesis induced by moderately emetogenic chemotherapy are scanty. An overview of the literature has been done that showed the efficacy of dexamethasone in two of three randomized trials. Its optimal dose and duration of administration has not been defined. Only one of four randomized studies showed a statistically significant efficacy of 5-HT(3) antagonists. Finally, only weak evidence has been published on the efficacy of dopamine receptor antagonists.

• Authors: Fausto Roila, David Warr, Rebecca A Clark-Snow, Maurizio Tonato, Richard J Gralla, Lawrence H Einhorn, Jorn Herrstedt
• Journal: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer (Support Care Cancer) Vol. 13 Issue 2 Pg. 104-8 (Feb 2005) ISSN: 0941-4355 [Print] Germany
• PMID: 15549426 (Publication Type: Journal Article, Review)

Chemical References

• Antiemetics
• Antineoplastic Agents
• Dopamine Antagonists
• Serotonin 5-HT3 Receptor Antagonists
• Dexamethasone

Topics

• Antiemetics (standards, therapeutic use)
• Antineoplastic Agents (adverse effects, classification)
• Clinical Trials as Topic
• Dexamethasone (standards, therapeutic use)
• Dopamine Antagonists (standards, therapeutic use)
• Drug Administration Routes
• Drug Administration Schedule
• Drug Therapy, Combination
• Humans
• Practice Guidelines as Topic
• Serotonin 5-HT3 Receptor Antagonists
• Vomiting (chemically induced, prevention & control)